UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study

Breast cancer research and treatment, 2019-06, Vol.175 (3), p.595-603

2019

Volltextzugriff (PDF)

P111 A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP vs ddAC-THP in high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11)

Breast (Edinburgh), 2023-04, Vol.68, p.S57-S57

2023

Volltextzugriff (PDF)

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Annals of oncology, 2019-10, Vol.30, p.v485-v486

2019

Volltextzugriff (PDF)

MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii147

2018

Volltextzugriff (PDF)

Phase I trial of dasatinib and ixabepilone in patients with solid tumors

Investigational new drugs, 2013-02, Vol.31 (1), p.92-98

2013

Volltextzugriff (PDF)

328TiP Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09

Annals of oncology, 2021-09, Vol.32, p.S507-S508

2021

Volltextzugriff (PDF)

Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

Annals of oncology, 2019-10, Vol.30, p.v477

2019

Volltextzugriff (PDF)

1190PD - Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Annals of oncology, 2019-10, Vol.30, p.v485-v486

2019

Volltextzugriff (PDF)

1191O - Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

Annals of oncology, 2019-10, Vol.30, p.v477-v477

2019

Volltextzugriff (PDF)

1190PDPhase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1191OPhase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Abstract OT3-05-03: MEDIOLA: An open-label, phase I/II basket study of olaparib (PARP inhibitor) and durvalumab (anti-PD-L1 antibody)–Additional breast cancer cohorts

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT3-05-03-OT3-05-03

2019

Volltextzugriff (PDF)

Abstract PD5-04: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA -mutated (g BRCA m) metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.PD5-04-PD5-04

2019

Volltextzugriff (PDF)

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Gynecologic oncology, 2018-06, Vol.149, p.246-247

2018

Volltextzugriff (PDF)

OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)

Annals of oncology, 2017-09, Vol.28, p.v67-v67

2017

Volltextzugriff (PDF)

Abstract P3-10-02: Increasing participation in research - breast cancer (Inspire-BrC)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P3-P3-10-02

2017

Volltextzugriff (PDF)

448TiPMEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

P1.15-004 An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S2044-S2045

2017

Volltextzugriff (PDF)

Meta-analysis: Should It be More Than the Sum of Its Parts?

JNCI : Journal of the National Cancer Institute, 2010-12, Vol.102 (24), p.1817-1819

2010

Volltextzugriff (PDF)

Abstract OT1-1-12: SAFE-HEaRt: A pilot study assessing the cardiac SAFEty of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.OT1-1-12-OT1-1-12

2013

Volltextzugriff (PDF)

ber die Fortpflanzungsgeschwindigkeit von Longitudinalwellen in Gelatine

The European physical journal. A, Hadrons and nuclei, 1920-05, Vol.3 (3), p.182-195

Herbolsheimer, P.

1920

Volltextzugriff (PDF)

Genome-wide Map of Nucleosome Acetylation and Methylation in Yeast

Cell, 2005-08, Vol.122 (4), p.517-527

2005

Volltextzugriff (PDF)

Association Between Osteoarthritis and Social Isolation: Data From the EPOSA Study

Journal of the American Geriatrics Society (JAGS), 2020-01, Vol.68 (1), p.87-95

2020

Volltextzugriff (PDF)

Minimal clinically important decline in physical function over one year: EPOSA study

BMC musculoskeletal disorders, 2019-05, Vol.20 (1), p.227-227, Article 227

2019

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(37)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study

P111 A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP vs ddAC-THP in high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11)

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

Phase I trial of dasatinib and ixabepilone in patients with solid tumors

328TiP Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09

Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

1190PD - Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

1191O - Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

1190PDPhase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

1191OPhase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

Abstract OT3-05-03: MEDIOLA: An open-label, phase I/II basket study of olaparib (PARP inhibitor) and durvalumab (anti-PD-L1 antibody)–Additional breast cancer cohorts

Abstract PD5-04: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA -mutated (g BRCA m) metastatic breast cancer (MBC)

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)

Abstract P3-10-02: Increasing participation in research - breast cancer (Inspire-BrC)

448TiPMEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts

P1.15-004 An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC

Meta-analysis: Should It be More Than the Sum of Its Parts?

Abstract OT1-1-12: SAFE-HEaRt: A pilot study assessing the cardiac SAFEty of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function

ber die Fortpflanzungsgeschwindigkeit von Longitudinalwellen in Gelatine

Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells

Genome-wide Map of Nucleosome Acetylation and Methylation in Yeast

Association Between Osteoarthritis and Social Isolation: Data From the EPOSA Study

Minimal clinically important decline in physical function over one year: EPOSA study

Suchergebnisse filtern